Propanc Biopharma (PPCB) vs PRF Technologies (PRFX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Propanc Biopharma is the larger company by market cap ($1.9 million vs $1.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PPCB | PRFX |
|---|---|---|
| Share price | $1.78 | $0.4758 |
| Market cap | $1.87M | $1.66M |
| 1-day change | +3.19% | -23.68% |
| EPS (TTM) | $-95.92 | $-4.09 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $17.00K |
| Net income (latest FY) | $-18.86M | $-5.02M |
| Gross margin | — | -311.76% |
| Operating margin | — | -30129.41% |
| Net margin | — | -29541.18% |
| 52-week high | $315.00 | $7.95 |
| 52-week low | $1.61 | $0.46 |
| Distance from 52-week high | -99.43% | -94.02% |
| Average volume | 188.66K | 228.55K |
| Shares outstanding | 1.05M | 3.50M |
| Employees | 2 | 6 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Propanc Biopharma
PPCB stock →Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
About PRF Technologies
PRFX stock →PRF Technologies Ltd., a specialty pharmaceutical company, focuses on reformulation of established therapeutics in Israel. It develops OcuRing-K, a bio-erodible sustained-release implant applied to the haptic of an intraocular lens for use in cataract surgery; and PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
PPCB vs PRFX FAQ
Which is bigger, Propanc Biopharma or PRF Technologies?
Propanc Biopharma (PPCB) is larger, with a market capitalization of $1.87M compared with $1.66M for PRF Technologies (PRFX).
Are Propanc Biopharma and PRF Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.